Dupilumab (Dupixent, Sanofi & Regeneron) Performs Well in AD Patients With Darker Skin Tones
Dupilumab (Dupixent, Sanofi & Regeneron) achieved 75% or greater improvement in overall atopic dermatitis (AD) disease severity in more than three-quarters of patiemts with darler skin tones, according to a Phase 4 study presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, TN.